Biovie INC S-1 registration statements

BioVie Inc. is registering for an offering of up to 16,025,641 shares of Class A Common Stock, along with accompanying warrants, and up to 16,025,641 pre-funded warrants.

BioVie Inc. has filed an S-1/A amendment detailing plans for a public offering of up to 56,390,977 shares of Class A Common Stock, alongside pre-funded warrants, while also addressing ongoing litigation and clinical trial updates.

BioVie Inc. has filed an S-1/A amendment detailing an offering of up to 56,390,977 shares of Class A Common Stock and a similar number of pre-funded warrants.

BioVie Inc. has filed an S-1 registration statement with the SEC to offer shares of Class A Common Stock and pre-funded warrants, aiming to raise capital for general corporate purposes.

BioVie Inc. is offering 1.98 million units of common stock and warrants to raise $13.5 million, while navigating clinical trial challenges and ongoing litigation.

BioVie Inc. announced a public offering to raise approximately $13.5 million for working capital, while grappling with significant clinical trial integrity issues, ongoing litigation, and a 'going concern' warning despite reduced net losses.

BioVie Inc., a clinical-stage biopharmaceutical company, has filed an amended S-1 registration statement for a public offering of units to raise approximately $13.5 million, as it navigates significant clinical trial protocol violations for its Alzheimer's drug candidate and addresses a 'going concern' doubt from its auditors.

BioVie Inc. has filed a registration statement for a public offering of units and pre-funded units, aiming to raise capital for its clinical-stage drug development programs while facing significant dilution and potential Nasdaq delisting risks.

BioVie Inc. has filed an amendment to its S-1 registration statement to correct a scrivener's error regarding the aggregate total of shares being registered.

BioVie Inc. has filed a registration statement for the resale of up to 7,711,613 shares of its common stock by selling stockholders, stemming from the exercise of warrants issued in recent private placements.